Latest news with #KVUE
New York Post
a day ago
- New York Post
Texas Target shooting leaves 2 dead, several others hurt, including child
Two people were killed and several others, including a child, were injured in a shooting at a Target in central Texas late Monday afternoon, officials said. A suspect was detained following the bloodshed at a Target north of Austin, according to police. At least two people were killed in a shooting at an Austin, Texas Target store on Monday. Fox7 Advertisement Officials told KVUE that between three and five victims were shot, including a child – who is not among the dead. The Austin-Travis County Emergency Medical Services told Fox 7 that it was treating four patients involved in the shooting. Advertisement The suspect was described as a white man wearing khaki shorts and a Hawaiian or floral shirt. This is a breaking story. Please check back for updates.
Washington Post
6 days ago
- Business
- Washington Post
Kenvue: Q2 Earnings Snapshot
SUMMIT, N.J. — SUMMIT, N.J. — Kenvue Inc. (KVUE) on Thursday reported second-quarter earnings of $420 million. The Summit, New Jersey-based company said it had profit of 22 cents per share. Earnings, adjusted for one-time gains and costs, came to 29 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 28 cents per share.
Yahoo
18-07-2025
- Business
- Yahoo
Kenvue Stock Has Unusual Put Option Activity After Lower Q2 Sales and CEO Firing
Kenvue, Inc. (KVUE), which manufactures Band-Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO had left. Put options are showing unusually high volume today. KVUE is at $21.59 today, well off its highs after releasing disappointing Q1 sales results on May 8. That probably led to the CEO's ouster yesterday. But it could be a value investor's signal to consider buying into KVUE stock. More News from Barchart How to Buy Tesla for a 13% Discount, or Achieve a 26% Annual Return Nvidia Stock Is at a Peak - What's the Best Play Here for NVDA? Market Makers May Be Favorably Mispricing MARA Holdings Options: Here's How We Know Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Disappointing Q2 Results Yesterday, Kenvue reported preliminary Q2 sales will be 4% lower, and 'organic' sales would be -4.2%. The company said it would update its 2025 outlook on Aug. 7. This was after disappointing Q1 sales. On May 8, Kenvue reported 3.9% Y/Y lower Q1 sales, although its gross margin rose slightly to 58% from 57.6%. In addition, its operating income margin rose to 14.9% from 14.1%. However, in its updated Q1 outlook, Kenvue said it expects a lower operating income margin for the full year 2025. But it did not give an exact number. It is trying to 'mitigate' the effects of tariffs on its future performance. In yesterday's announcement about the CEO's leaving (after having ousted the CFO on May 12), the company is making a clean sweep of its upper management. Moreover, Kenvue said it's looking to unlock shareholder value but did not give any concrete examples of what it plans to do. So, no wonder there has been heavy put option activity in KVUE stock. Unusual Put Option Activity Today, the Barchart Unusual Stock Options Activity Report shows that over 5,000 put options have traded at the $21.00 strike pricve in the July 25 expiration contract, expiring in 9 days. That is over 40 times the number of prior outstanding contracts at that strike price. This $21.00 strike is slightly lower than today's price, so it is out-of-the-money (OTM). The premium at the midpoint is 24 cents, so that means buyers of the puts hope to see KVUE close below $20.76, or 3.4% below today's trading price. However, sellers of the puts, who may have received just 18 cents on the bid side, are making an immediate yield of 0.86% (i.e., $0.18/$21.00). At the midpoint premium, the short-put yield is slightly higher at 1.14% (i.e., $0.24/$21.00). So, on average, short sellers of the puts are making around 1.0% for 9 days until expiration. In effect, they may be willing to buy shares at $21.00 if KVUE falls to that price on or before July 25. That may or may not be a good buy, based on the stock's outlook. Price Target for KVUE Stock Right now, there is a good deal of fear that tariffs could upset Kenvue's operating income and net income. But, has this already been discounted in the stock price? For example, analysts now project $1.13 earnings per share (EPS) this year and $1.21 next year. That puts KVUE stock on a forward price/earnings (P/E) multiple of 18.5x $21.59 price / $1.17 next 12 months (NTM) EPS = 18.45x This is slightly higher than its average over the past two years. For example, Morningstar reports that in 2023 and 2024 its forward P/E multiples were around 16.4x. That implies the stock could be worth $19.19 per share, or 11% lower. Moreover, using the 2026 EPS, the stock would still only be worth $19.84, or -8% downside from today. However, the company has said it expects to implement a series of shareholder value actions. Let's hope that they will help improve the outlook for the stock's valuation. As a result, it may be that the buyers of these puts could end up making more money than the short-sellers of these puts. The bottom line is that until the company updates its 2025 and further outlook, based on tariff impacts, KVUE stock may be in a transition period. As a result, investors should be careful about taking a strong directional position or copying these unusual options trades until there is more clarity. On the date of publication, Mark R. Hake, CFA did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
16-07-2025
- Business
- Yahoo
Kenvue's Q2 2025 Earnings: What to Expect
Skillman, New Jersey-based Kenvue Inc. (KVUE) operates as a global consumer health company. Valued at $41.9 billion by market cap, the company offers a consumer health portfolio in self-care, skin health & beauty, and essential health products. The world's largest pure-play consumer health company is expected to announce its fiscal second-quarter earnings for 2025 on Tuesday, Aug. 5. Ahead of the event, analysts expect KVUE to report a profit of $0.28 per share on a diluted basis, down 12.5% from $0.32 per share in the year-ago quarter. The company beat or matched the consensus estimate in each of the last four quarters. Dear Nvidia Stock Fans, Mark Your Calendars for July 16 How to Buy Tesla for a 13% Discount, or Achieve a 26% Annual Return Retirement Ready: 3 Dividend Stocks to Set and Forget Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For the full year, analysts expect KVUE to report EPS of $1.12, down 1.8% from $1.14 in fiscal 2024. However, its EPS is expected to rise 8.9% year over year to $1.22 in fiscal 2026. KVUE stock has outperformed the S&P 500 Index's ($SPX) 10.9% gains over the past 52 weeks, with shares up 18.1% during this period. Similarly, it outperformed the Consumer Staples Select Sector SPDR Fund's (XLP) 4% gains over the same time frame. On May 8, KVUE shares closed up more than 4% after reporting its Q1 results. Its adjusted EPS of $0.24 topped Wall Street expectations of $0.22. The company's revenue was $3.74 billion, topping Wall Street forecasts of $3.68 billion. Analysts' consensus opinion on KVUE stock is reasonably bullish, with a 'Moderate Buy' rating overall. Out of 15 analysts covering the stock, five advise a 'Strong Buy' rating, and 10 give a 'Hold.' KVUE's average analyst price target is $24.50, indicating a potential upside of 14.5% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
Listerine Maker Kenvue Names Interim CEO, Explores Strategic Alternatives
Kenvue (KVUE) on Monday named an interim chief executive, while the consumer health company said it
